Hepatitis C: The Pan-Virals Are on the Way

Article

Pan-virals show potential to work across all HCV genotypes.

Pan-virals show potential to work across all HCV genotypes.

With the ever-growing arsenal of antivirals to cure hepatitis C infection, physicians still have to be mindful of which of the 6 hepatitis virus genotypes their patient has. No drug work for all genotypes.

That could change next year. The pan-virals are coming.

Speaking at a symposium on treatments for hepatitis C at the American College of Gastroenterology Annual Scientific Meeting in Honolulu Oct 18, Mitchell Shiffman, MD, director of the Liver Institute of Virginia, Bon Secours Health System, Richmond, VA, said the newest drug candidates are expected to work on all genotypes of the virus.

The drugs include Merck’s grazoprevir and elbasvir, to be given as a fixed dose combo. Shiffman said FDA approval is expected by the middle of 2016. Gilead’s combination of sofosbuvir and velpatasvir is also expected to debut, he said.

There are currently more than a dozen antivirals approved for hepatitis C, several of them combos, and sorting out which ones work best for which patients is complicated.

Physicians also need to pay close attention to potential drug-drug reactions, Shiffman noted. Dangerous interactions include anti-seizure drugs, some antimicrobials, some HIV drugs, antifungals, immunosuppressive drugs, and even some oral contraceptives.

Patients whose co-morbidities include heart disease should not take the antivirals in combination with amiodarone, Shiffman said.

“Consult with the cardiologist and see if there is another [heart] drug,” he cautioned.

Herbal remedies may not even be on physicians’ radar but they can pose hazards too. St. John’s wort, for instance, interferes with the mechanisms by which some of the antivirals disrupt the virus’ ability to replicate. Even high-dose PPIs can be problematic, Shiffman said.

On Shiffman’s list of questions for patients, is whether they have cirrhosis, co-morbidities, HIV, and whether they are active drug users. Though there has been much debate on the ethics of whether to force infected patients to prove that they have not used injection drugs for a sustained period of time, Shiffman said “I am very leery of treating active drug-users.”

Another hurdle to effective treatment can be insurers that balk at the prices of the antivirals. Treatment time can also vary, with patients with a cirrhosis often needing the drugs for 24 weeks instead of the usual regimen of 12 weeks.

The prescribing picture may be complicated, but the payoff is huge, Shiffman added.

“All these drugs are showing excellent sustained viral response,” he said.

Related Videos
male pharmacist using digital tablet during inventory in pharmacy | Image Credit: sofiko14 - stock.adobe.com
Pharmacist holding medicine box in pharmacy drugstore. | Image Credit: I Viewfinder - stock.adobe.com
Pharmacy Drugstore Checkout Cashier Counter | Image Credit: Gorodenkoff - stock.adobe.com
Medicine tablets on counting tray with counting spatula at pharmacy | Image Credit: sutlafk - stock.adobe.com
Capsules medicine and white medicine bottles on table | Image Credit: Satawat - stock.adobe.com
Human cell or Embryonic stem cell microscope background | Image Credit: Anusorn - stock.adobe.com
Concept of health care, pharmaceutical business, drug prices, pharmacy, medicine and economics | Image Credit: Oleg - stock.adobe.com
Biosimilar pharmaceutical drug bottle on blue background. | Image Credit: Carl - stock.adobe.com
Pharmaceutical manufacture background with glass bottles with clear liquid on automatic conveyor line. | Image Credit: wacomka - stock.adobe.com
Bottle and scattered pills on color background, top view | Image Credit: New Africa - stock.adobe.com
© 2024 MJH Life Sciences

All rights reserved.